back to Australia directory
australia clinical guidance

Urticaria and angioedema (non-anaphylaxis)

A detailed Australian summary of urticaria and angioedema (non-anaphylaxis), with source-attributed priorities, a practical workflow, safety escalation and state or territory implementation boundaries.

JurisdictionAustralia
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Australia
This is an iatroX educational summary of named Australia sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Apply current TGA product information, PBS restrictions, state or territory law, local referral criteria, formulary and antimicrobial policy. A national recommendation does not create uniform service access.

Scope

Confirm transient individual wheals lasting less than a day and separate urticaria from urticarial vasculitis, contact dermatitis and mast-cell disorders. Assess airway, breathing and circulation first; angioedema with respiratory or cardiovascular involvement is anaphylaxis even if wheals are absent. This summary is limited to the population, decisions and escalation boundaries stated in the named source.
sources for this section:ASCIA urticaria guideline

The Bottom Line

  • Confirm transient individual wheals lasting less than a day and separate urticaria from urticarial vasculitis, contact dermatitis and mast-cell disorders.
  • Assess airway, breathing and circulation first; angioedema with respiratory or cardiovascular involvement is anaphylaxis even if wheals are absent.
  • Wheals persisting in one site beyond twenty-four hours with bruising or pain raises urticarial vasculitis and needs investigation.
  • Look for medicine and physical triggers, infection and inducible patterns, but avoid broad allergy panels in typical chronic spontaneous urticaria.
sources for this section:ASCIA urticaria guideline

Practical clinical workflow

1

Topic-specific assessment action

Confirm transient individual wheals lasting less than a day and separate urticaria from urticarial vasculitis, contact dermatitis and mast-cell disorders.
2

Topic-specific diagnostic action

Look for medicine and physical triggers, infection and inducible patterns, but avoid broad allergy panels in typical chronic spontaneous urticaria.
3

Topic-specific management action

Use regular non-sedating antihistamine under ASCIA guidance and review sedation, driving and escalation rather than relying on repeated corticosteroid bursts.
4

Topic-specific follow-through

ACE-inhibitor angioedema can recur after medicine cessation and usually lacks itch or wheals; airway risk determines emergency care.
sources for this section:ASCIA urticaria guideline

Safety boundaries and escalation

  • Tongue or laryngeal swelling, voice change, stridor, wheeze, hypotension or rapid progression requires immediate intramuscular adrenaline and emergency care.
  • Chronic spontaneous urticaria is rarely caused by a single food, so indiscriminate exclusion diets can create harm without benefit.
sources for this section:ASCIA urticaria guideline

Implementation

The named source is national or binational guidance used in Australia, but referral access, public-health directions, formularies and funded services can still differ by state, territory and health service. Check current TGA product information for medicines. Offer culturally safe care and use the NACCHO鈥揜ACGP National Guide where Aboriginal and Torres Strait Islander preventive or chronic-care recommendations differ.
sources for this section:ASCIA urticaria guideline

Clinical use boundary

This independently written summary is not an official guideline. Check the linked source version, current TGA-approved product information where medicines are involved, and the applicable state, territory and local pathway at the point of care.

sources for this section:ASCIA urticaria guideline

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Australasian Society of Clinical Immunology and AllergyChronic Spontaneous Urticaria Position Paper and Treatment GuidelinesJuly 2020 Australian treatment guideline; current status checked 2026-08-20 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Australia question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.